Business context and reporting period
GSK plc filed this Form 6-K on October 13, 2026, reporting transactions by persons discharging managerial responsibilities (PDMRs) and persons closely associated with them (PCAs). This is a transaction notification, not a financial-results filing.
Reported transactions
All reported acquisitions followed reinvestment of dividends paid to shareholders on October 8, 2026. Ordinary shares traded on the London Stock Exchange at £17.5904 per share; ADSs traded on the New York Stock Exchange at $46.5883 per ADS.
| Person | Instrument | Quantity | Transaction date |
|---|---|---|---|
| Luke Miels, CEO | Ordinary shares | 23.331 | October 8, 2026 |
| Lynn Baxter, President, Europe | Ordinary shares | 297.818 | October 8, 2026 |
| Mike Crichton, President, International | Ordinary shares | 1.100 | October 8, 2026 |
| James Ford, SVP and Group General Counsel, Legal and Compliance | Ordinary shares | 2,014.345 | October 8, 2026 |
| Nina Mojas, President, Global Product Strategy | Ordinary shares | 246.181 | October 8, 2026 |
| Roanne Parry, Chief People Officer | Ordinary shares | 1.400 | October 8, 2026 |
| David Redfern, President, Corporate Development | Ordinary shares | 6,532.657 | October 8, 2026 |
| Regis Simard, President, Global Supply Chain | Ordinary shares | 2,999.067 | October 8, 2026 |
| Philip Thomson, President, Global Affairs | Ordinary shares | 2,707.449 | October 8, 2026 |
| Deborah Waterhouse, CEO, ViiV Healthcare and President, Global Health | Ordinary shares | 1,204.461 | October 8, 2026 |
| Tony Wood, Chief Scientific Officer | Ordinary shares | 2,558.851 | October 8, 2026 |
| Neil Falkingham, PCA of Lynn Baxter | Ordinary shares | 169.615 | October 8, 2026 |
| Kate Thomson, PCA of Philip Thomson | Ordinary shares | 112.233 | October 8, 2026 |
| Elizabeth McKee Anderson, Independent Non-Executive Director | ADSs | 41 | October 9, 2026 |
| Charles Bancroft, Senior Independent Non-Executive Director | ADSs | 412 | October 9, 2026 |
| Dr Hal Barron, Non-Executive Director | ADSs | 32 | October 9, 2026 |
| Dr Anne Beal, Independent Non-Executive Director | ADSs | 47 | October 9, 2026 |
| Dr Harry Dietz, Independent Non-Executive Director | ADSs | 45 | October 9, 2026 |
| Dr Jeannie Lee, Independent Non-Executive Director | ADSs | 27 | October 9, 2026 |
| Dr Vishal Sikka, Independent Non-Executive Director | ADSs | 136 | October 9, 2026 |
Financial metrics and comparison
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, guidance, or comparable-period financial information. It reports no material change to business performance.
Outlook, risks and unusual items
No outlook, management commentary, risks, contingencies, or unusual operating items are discussed. The disclosed transactions are dividend reinvestments; the filing does not describe them as discretionary market purchases.
Important facts to verify
- Confirm the reported transaction quantities, prices, dates, and exchange venues against the original notices.
- Verify the dividend-reinvestment context and whether any subsequent ownership balances are disclosed elsewhere.
- Consult GSK’s periodic financial filings for current operating results, liquidity, debt, and outlook; this 6-K does not provide those metrics.